このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

肝移植を待つ患者のためのオンラインリハビリテーション (OPAL)

2026年11月2日 更新者:University of Alberta

OPAL: 肝移植を待つ患者のためのオンラインプレハビリテーション - 身体的虚弱を軽減し、健康転帰を改善するための多施設ランダム化対照試験

Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.

The proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.

The primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.

調査の概要

状態

積極的、募集していない

詳細な説明

This multi-centre randomized controlled trial (RCT) will be completed across the six major LT programs in Canada: Vancouver, Edmonton, Calgary, Toronto, London, and Montreal.

Participants involved in this study will be LT transplant candidates with cirrhosis who are receiving care at one of the six participating LT programs.

Participants will be assessed for eligibility, provided informed signed consent, complete baseline testing and then be randomized to the prehabilitation arm or usual care. Participants will be randomized in a 2:1 ratio between groups.

Prehabilitation Arm:

The 12 week prehabilitation program includes exercise, nutrition and psychological components that is accessed through the online digital web platform.

  • The nutrition program includes a nutritional assessment, provision of a daily protein intake target (1.2-1.5 g/kg/day), online group sessions, and follow ups. Participants will also be provided with a clinically tested whey protein powder supplement with dosage based on their malnutrition scoring done at baseline. Follow ups will also be provided based on malnutrition scoring done at baseline.
  • The exercise program includes an exercise assessment, follow along exercise videos, and weekly virtual live exercise sessions. The exercise specialist will advise one of three levels of exercise programming for each participant. Participants will be advised to complete 3 exercise sessions weekly from a combination of virtual group sessions and follow along videos and to participate in planned aerobic activity as much as possible.
  • The weekly acceptance and commitment therapy based educational videos focus on reducing stress and anxiety and improving motivation and adherence.

Control/Usual Care Arm:

This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. A short questionnaire will be sent to control participants every 4 weeks to track changes in physical activity.

Post-Transplant follow-up In the subgroup of patients who undergo LT, the same in-person and virtual testing will be carried out at 12 weeks post-transplant (timing may vary due to site clinic flow)

Data Collection Plan

Sample size calculations are based on the primary outcome (the chair stand test: time to complete 5 sit-to-stands) using individual data from our local exercise study in cirrhosis (n=59), plus our sit-to-stand data from our study of 694 patients. After accounting for lack of trial completion, loss to follow up, the total sample size is 177, with 59 participants in the control and 118 in the intervention arm.

  1. Quantitative outcomes: Baseline and primary/secondary/exploratory outcome data will be collected with in-person and/or virtual visits at baseline, week 12 (end of trial) and 12 weeks post-transplant (in the subgroup of patients who undergo LT). Charts will be reviewed for information on death, hospitalization, ambulatory care visits, medications and transplantation for up to 2 years after randomization in all participants. Dietary intake data (24-hour recall) may be collected using third party software.
  2. Qualitative data: Interviews/Focus groups will be conducted at the end of the study in a virtual format. Participation in the interviews/focus groups will be optional.

Types of analyses

  1. Quantitative outcomes: Baseline demographic and clinical characteristics will be compared between groups to identify differences that may exist despite randomization. Continuous variables will be screened for assumptions of normality, and descriptive analyses will be presented for participant demographics, medical and outcome variables. Sex will be used in subgroup analysis of primary and secondary outcomes. It will also be a covariate for exploratory analysis in corresponding models. All analyses will adhere to the intention-to-treat principle.
  2. Qualitative data: Qualitative data will be analyzed inductively following a theoretical thematic approach. Data will be coded, with codes combined into larger categories and theme, with the goal of highlighting participant experiences and acceptability (barriers, facilitators) of the OPAL platform and intervention. Data collection and analysis will occur concurrently in order to enable refinement of interview/focus guide questions and deeper exploration of emerging themes.

Primary outcome: The primary outcome (sit to stand test; time to do 5 sit-to-stands) will be analyzed by linear mixed models with random effects, adjusted for baseline score as a covariate. Sites will be entered as random effects.

Secondary/exploratory outcomes: (1) Quantitative outcomes: Similar types of models will be used for continuous secondary/exploratory outcomes. To examine predictors of exercise and nutrition adherence (e.g. COM-B results), generalized linear models with binary outcome will be employed. To evaluate the potential effect of selected demographic variables on outcomes, as an exploratory analysis, models will be adjusted for clinically significant variables (e.g. sex, gender, digital technology proficiency). Results will be primarily descriptive. Exploratory per-protocol analysis will be performed, and the results will be presented if substantial differences are found between this group and the intention-to-treat group.

研究の種類

介入

入学 (実際)

179

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alberta
      • Calgary、Alberta、カナダ、T2N 2T9
        • Foothills Medical Centre
      • Edmonton、Alberta、カナダ、T6G1Z1
        • Kaye Edmonton Clinic
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 1M9
        • Gordon and Leslie Diamond Health Care Centre
    • Ontario
      • London、Ontario、カナダ、N6A 5W9
        • London Health Sciences Centre
      • Toronto、Ontario、カナダ、M5G 0A3
        • Toronto General Hospital - Ajmera Transplant Centre
    • Quebec
      • Montreal、Quebec、カナダ、H4A3J1
        • McGill University Health Centre

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.

Exclusion Criteria:

  • Listed for living related donor transplantation with expected time on the wait list <12 weeks, or model for end-stage liver disease (MELD-Na) Score >26 (Justification: time to transplant is very short)
  • Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)
  • Unable to provide informed consent
  • Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation
  • Life expectancy less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)
  • Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure
  • Transplant indication is cholangiocarcinoma.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Prehabilitation Group

The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.

12-weeks of online prehabilitation programming including:

1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.

2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).

3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence.

介入なし:Usual Care

This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in time to do 5-sit-to-stands from baseline
時間枠:Week 0

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Week 0
Change in time to do 5-sit-to-stands from baseline
時間枠:Week 12

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in liver frailty index from baseline
時間枠:Week 0

Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization.

The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail).

Higher scores mean a worse outcome.

Week 0
Change in liver frailty index from baseline
時間枠:Week 12

Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization.

The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail).

Higher scores mean a worse outcome.

Week 12
Changes in virtual physical function testing over time (2-min step test)
時間枠:Week 0

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 0
Changes in virtual physical function testing over time (2-min step test)
時間枠:Week 12

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 12
Change in health-related quality of life from baseline (CLDQ)
時間枠:Week 0

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 0
Change in health-related quality of life from baseline (CLDQ)
時間枠:Week 12

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
時間枠:Week 0

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 0
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
時間枠:Week 12

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 12
Qualitative Acceptability Data
時間枠:Week 12

Inductive analysis of post-trial semi-structured interviews/focus groups with participants

Week 12

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in time to do 5-sit-to-stands from baseline
時間枠:Week 8

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Completed at week 8 to account for the possibility of transplantation or loss-to-follow-up before the end of the 12 weeks.

Week 8
Change in sarcopenia from baseline
時間枠:Week 0

Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

Week 0
Change in sarcopenia from baseline
時間枠:Week 12

Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

Week 12
Change in distance in the 6 minute walk test from baseline
時間枠:Week 0

6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

Week 0
Change in distance in the 6 minute walk test from baseline
時間枠:Week 12

6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

Week 12
Change in covert hepatic encephalopathy from baseline
時間枠:Week 0

The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

Week 0
Change in covert hepatic encephalopathy from baseline
時間枠:Week 12

The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
時間枠:Week 8

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 8
Change in health-related quality of life from baseline (CLDQ)
時間枠:Week 8

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 8
Change in 6-item COM-B scale over time during intervention
時間枠:Week 4

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

Week 4
Change in 6-item COM-B scale over time during intervention
時間枠:Week 8

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

Week 8
Change in 6-item COM-B scale over time during intervention
時間枠:Week 12

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
時間枠:Post-transplant (12 weeks after transplant date)

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Post-transplant (12 weeks after transplant date)
Change in health-related quality of life from baseline (CLDQ)
時間枠:Post-transplant (12 weeks after transplant date)

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (Single leg balance test)
時間枠:Week 0

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 0
Changes in virtual physical function testing over time (Single leg balance test)
時間枠:Week 8

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 8
Changes in virtual physical function testing over time (Single leg balance test)
時間枠:Week 12

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 12
Changes in virtual physical function testing over time (Single leg balance test)
時間枠:Post-transplant (12 weeks after transplant date)

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (2-min step test)
時間枠:Week 8

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 8
Changes in virtual physical function testing over time (2-min step test)
時間枠:Post-transplant (12 weeks after transplant date)

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Post-transplant (12 weeks after transplant date)
Number of participants who died during the 12 week trial
時間枠:Week 12

Death will be collected through chart review

Week 12
Number of hospitalizations and ambulatory clinic visits during the 12 week trial
時間枠:Week 12

Hospitalizations and ambulatory clinic visits will be collected through chart review

Week 12
Number of participants who were transplanted during the 12 week trial
時間枠:Week 12

Data on transplantations occurring during the trial will be collected through chart review

Week 12
Number of participants who died during the 2 years post-study completion
時間枠:2 years post-study completion

Death will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Number of hospitalizations and ambulatory clinic visits during the 2 years post-study completion
時間枠:2 years post-study completion

Hospitalizations and ambulatory clinic visits will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Number of participants who were transplanted during the 2 years post-study completion
時間枠:2 years post-study completion

Data on transplantations occurring during the trial will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Economic Evaluation
時間枠:Week 12

Healthcare access and hospital usage will be collected through patient survey.

Week 12
Total Length of stay at time of transplant
時間枠:Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain total length of stay at time of transplant

Post-transplant up to 3 months of the trial data collection period
Intensive care unit length of stay at time of post transplant
時間枠:Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain intensive care unit length of stay

Post-transplant up to 3 months of the trial data collection period
Days of mechanical ventilation at time of post transplant
時間枠:Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain days of mechanical ventilation

Post-transplant up to 3 months of the trial data collection period
Discharge location from hospital at time of transplant
時間枠:Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain discharge home from hospital (versus rehabilitation, nursing home or other institutional location)

Post-transplant up to 3 months of the trial data collection period
Readmissions within 30 days at time of transplant
時間枠:Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain any readmissions within 30 days.

Post-transplant up to 3 months of the trial data collection period
Malnutrition
時間枠:Week 0

The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes.

The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

Week 0
Malnutrition
時間枠:Week 12

The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes.

The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

Week 12
Adverse events
時間枠:Week 12

Major: death or hospitalization for an event occurring during or up to 3 h after exercise; cardiovascular events (stroke, myocardial infarction); permanent disability; angina, syncope, arrhythmia; variceal bleeding. Minor: hypoglycemia, hyper- or hypotension requiring medical attention, musculoskeletal injury or fall.

Week 12
Changes in health care provider support from baseline
時間枠:Week 0

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 0
Changes in physical activity levels from baseline
時間枠:Week 0

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 0
Changes in health care provider support from baseline
時間枠:Week 4

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 4
Changes in physical activity levels from baseline
時間枠:Week 4

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 4
Changes in health care provider support from baseline
時間枠:Week 8

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 8
Changes in physical activity levels from baseline
時間枠:Week 8

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 8
Changes in health care provider support from baseline
時間枠:Week 12

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 12
Changes in physical activity levels from baseline
時間枠:Week 12

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 12
Changes in functional status from baseline
時間枠:Week 0

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 0
Changes in functional status from baseline
時間枠:Week 8

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 8
Changes in functional status from baseline
時間枠:Week 12

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 12
Adherence to prehabilitation program goals
時間枠:Week 12

(i) 70% adherence to target protein intake and protein powder supplementation (assessed by dietary intake, nutrition check ins, platform metrics and monthly nutrition questionnaires), (ii) 70% adherence to exercise sessions (assessed by attendance, check ins, platform metrics) excluding study weeks with interruptions to programming due to health related issues (e.g. transplant dry runs, hospital admissions as these are common in patients awaiting LT)

Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Puneeta Tandon、University of Alberta

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年7月12日

一次修了 (実際)

2026年8月28日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2023年5月15日

QC基準を満たした最初の提出物

2023年6月2日

最初の投稿 (実際)

2023年6月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する